Delving into the Latest Updates on Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Respiratory Diseases

Antibody drug conjugate (ADC)

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Antibody drug conjugate (ADC)	3
Chemical drugs	1

Top 5 Target	Count

LRRC15(Leucine-rich repeat-containing protein 15)	1
RAS(RAS type GTPase family)	1
EGFR x Top I x c-Met	1
CDH17 x Top I	1

主要目的：第1部分（剂量递增）：评价SIM0532的安全性和耐受性，并确定最大耐受剂量（MTD）；第2部分（剂量扩展）：确定SIM0532的推荐剂量（RD）并初步评价SIM0532的抗肿瘤活性次要目的：进一步描述SIM0532的安全性和耐受性特征；描述SIM0532的药代动力学（PK）特性；进一步评价SIM0532的抗肿瘤活性

[Translation]

Primary Objectives: Part 1 (Dose Elevation): To evaluate the safety and tolerability of SIM0532 and determine the maximum tolerated dose (MTD); Part 2 (Dose Extension): To determine the recommended dose (RD) of SIM0532 and preliminarily evaluate its antitumor activity. Secondary Objectives: To further describe the safety and tolerability characteristics of SIM0532; to describe the pharmacokinetic (PK) properties of SIM0532; to further evaluate the antitumor activity of SIM0532.

Start Date-

Sponsor / Collaborator

Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si

[+1]

100 Clinical Results associated with Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si

Login to view more data

0 Patents (Medical) associated with Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si

Login to view more data

100 Deals associated with Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si

Login to view more data

100 Translational Medicine associated with Shang Hai Xian Wei Yi Yao Ke Ji You Xian Gong Si

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

3

Phase 1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SIM-0610 ( EGFR x Top I x c-Met )	Liver Cancer More	Phase 1
SIM0532 ( RAS )	Advanced Malignant Solid Neoplasm More	Phase 1
SIM-0609 ( CDH17 x Top I )	Solid tumor More	Phase 1
SIM0613 ( LRRC15 )	Solid tumor More	IND Application